J C LaRosa
Affiliation: State University of New York
- Understanding risk in hypercholesterolemiaJohn C LaRosa
State University of New York Downstate Medical Center, Brooklyn, New York 11203, USA
Clin Cardiol 26:I3-6. 2003..With the availability of statin therapy, we are now able to reduce the risk of major adverse CHD events by an average of 30%, regardless of patient age or gender...
- Low-density lipoprotein cholesterol reduction: the end is more important than the meansJohn C LaRosa
SUNY Downstate Medical Center, Brooklyn, New York, USA
Am J Cardiol 100:240-2. 2007....
- Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)John C LaRosa
State University of New York Health Science Center, New York, New York, USA
Am J Cardiol 100:747-52. 2007....
- Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular eventsJohn C LaRosa
State University of New York Health Science Center, New York, NY, USA
Am J Cardiol 111:1221-9. 2013..In conclusion, clinical trial evidence demonstrating the efficacy and safety of LDL cholesterol lowering to a very low level is essential to ascertain the benefits and risks in reducing the residual risk of vascular disease...
- Cardiovascular risk factors in minoritiesJohn C LaRosa
Office of the President, SUNY Downstate Medical Center, Brooklyn, NY 11203 2098, USA
Am J Med 118:1314-22. 2005..Risk factor intervention should be pursued in minority groups but with the understanding that clinical trials have not ruled out the possibility of qualitative or quantitative differences in response rates among different groups...
- Reduction of serum LDL-C levels: a relationship to clinical benefitsJohn C LaRosa
University of New York Health Center at Brooklyn, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA
Am J Cardiovasc Drugs 3:271-81. 2003..More potent agents in development are likely to make such levels more readily achievable, as well as making guideline targets attainable for many of the large number of patients who currently fail to reach them...
- New and emerging data from clinical trials of statinsJohn C LaRosa
State University of New York Downstate Medical Center, 450 Clarkson Avenue, Box 1, Brooklyn, NY 11203 2098, USA
Curr Atheroscler Rep 6:12-9. 2004....
- Evidence-based management of dyslipidemias in womenJohn C LaRosa
The State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
Curr Atheroscler Rep 5:379-85. 2003
- What do the statins tell us?John C LaRosa
State University of New York Health Science Center at Brooklyn, Brooklyn, NY 11203, USA
Am Heart J 144:S21-6. 2002....
- Outcomes of lipid-lowering treatment in postmenopausal womenJohn C LaRosa
State University of New York Health Science Center at Brooklyn, 11203, USA
Drugs Aging 19:595-604. 2002..Therapy for lipoprotein disorders in women and men is identical. For the overwhelming majority of patients, treatment with statin therapy is both highly efficacious and well tolerated...
- Highlighting the unmet need for prevention: an epidemiologic perspectiveJohn C LaRosa
State University of New York, Downstate Medical Center in Brooklyn, NY, USA
Postgrad Med 112:6-11. 2002..Urbanization, the trend toward a more sedentary lifestyle, and the abandonment of a vegetarian-based diet are among the premier underlying causes of ischemic heart disease today...
- Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial)John C LaRosa
State University of New York, Health Science Center, Brooklyn, New York, USA
Am J Cardiol 105:283-7. 2010..In TNT, analyses limited to the primary end point significantly underestimated the decrease in total cardiovascular disease burden achieved by intensive low-density lipoprotein cholesterol lowering...
- Intensive lipid lowering with atorvastatin in patients with stable coronary diseaseJohn C LaRosa
State University of New York Health Science Center, Brooklyn, NY 11203, USA
N Engl J Med 352:1425-35. 2005..We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD)...
- The benefits of statin therapy--what questions remain?Antonio M Gotto
Weill Medical College of Cornell University, Olin Hall, Room 205, 445 East 69th Street, New York, NY 10021, USA
Clin Cardiol 28:499-503. 2005..Early trials provided a solid foundation of knowledge on the efficacy and safety of statins. Recent and ongoing trials generate new data to resolve remaining questions in the fields of CHD prevention and lipidology...
- Prevention and treatment of coronary heart disease: who benefits?J C LaRosa
State University of New York Downstate Medical Center, Brooklyn, New York, USA
Circulation 104:1688-92. 2001..Several ongoing trials may resolve the controversies about which patient groups will benefit from different prevention and treatment strategies...
- Is aggressive lipid-lowering effective and safe in the older adult?John C LaRosa
State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
Clin Cardiol 28:404-7. 2005..This paper reviews the benefits of statin therapy in the elderly and discusses the reality versus the perception of risk, selection of appropriate patients, and ways in which any risks that may exist can be minimized further...
- Primary prevention: the unsettling questionJohn C LaRosa
SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
Curr Atheroscler Rep 7:1-2. 2005
- Use of statin drugs in womenJohn C LaRosa
State University of New York, Downstate Medical Center, Brooklyn, New York, USA
J Hypertens Suppl 20:S70-2. 2002..Patients at risk should receive cholesterol-lowering treatment with statin drugs to prevent both atherosclerotic morbidity and mortality...
- Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trialsJ C LaRosa
Office of the President, State University of New York Health Science Center at Brooklyn, 11203, USA
JAMA 282:2340-6. 1999..Lowering low-density lipoprotein cholesterol (LDL-C) is known to reduce risk of recurrent coronary heart disease in middle-aged men. However, this effect has been uncertain in elderly people and women...
- Past, present, and future standards for management of dyslipidemiaJohn C LaRosa
State University of New York Health Science Center, Brooklyn, New York 11203, USA
Am J Med 116:3S-8S. 2004....
- Chemoprevention of coronary atherosclerosis: the role of lipid interventions. A position paper of the American Council on Science and HealthJohn C LaRosa
State University of New York Health Science Center at Brooklyn, NY, USA
MedGenMed 4:12. 2002..Although more difficult to prove, earlier intervention can almost surely lower the risk of later, potentially lethal, coronary events...
- Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) studyDavid D Waters
University of California, San Francisco, California, USA
J Am Coll Cardiol 48:1793-9. 2006..We sought to assess the effects on cerebrovascular events of treating patients with stable coronary disease with low-density lipoprotein cholesterol (LDL-C) levels substantially below 100 mg/dl...
- Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets studyPrakash Deedwania
Veterans Affairs Central California Healthcare System and University of California San Francisco School of Medicine, San Francisco, CA, USA
Lancet 368:919-28. 2006....
- HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsPhilip Barter
Heart Research Institute, Sydney, Australia
N Engl J Med 357:1301-10. 2007..High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol...
- The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) studyJohn B Kostis
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903 0019, USA
J Clin Hypertens (Greenwich) 10:367-76. 2008..The effect of lower SBP on stroke was most pronounced in the lowest LDL-C tertile...
- Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgerySanjiv J Shah
Division of Cardiology, San Francisco General Hospital, University of California, San Francisco, California 94110, USA
J Am Coll Cardiol 51:1938-43. 2008....
- Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatmentJohn J P Kastelein
Academic Medical Center, Department of Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands
Circulation 117:3002-9. 2008....
- Justifying lipid-lowering therapy in persons >/=65 years of ageJohn C LaRosa
Am J Cardiol 90:1330-2. 2002
- Means and ends of statins and low-density lipoprotein cholesterol loweringJohn C LaRosa
J Am Coll Cardiol 50:419-20. 2007
- Cholesterol and coronary disease--the altered landscapeJohn C LaRosa
Cardiovasc Drugs Ther 18:9-10. 2004
- At the heart of the statin benefitJohn C LaRosa
J Am Coll Cardiol 46:1863. 2005